Huang HH, et al. - Using the Taiwan Cancer Registry Database and the National Health Insurance Research Database, researchers assessed the roles of rituximab maintenance for newly diagnosed follicular lymphoma (FL) patients in Taiwan. Three hundred and ninety-six patients with stage II-IV diseases receiving 4-8 cycles of rituximab-containing induction chemotherapies (R-induction) were enrolled. Of these, 260 underwent rituximab maintenance (R-maintenance group), and 136 served as the observation group. The R-maintenance group exhibited a significantly better OS in both the univariate and multivariate analyses (after adjusting for age, sex, and Ann Arbor stages), even with less anthracycline and fewer cycles of R-induction than the observation group. This study represents the first nationwide study establishing the overall survival benefit of rituximab maintenance after induction therapies in newly diagnosed FL patients from Asian populations.